Biophytis raises €2m in Series B funding round

The company will use the funds to develop its nutraceuticals pipeline as well as drug candidates derived from nutraceutical active substances for the treatment of metabolic and age-related diseases.

Metabrain Research, a spin-off of Merck Serono, has joined existing investors Seventure partners and CM-CIC Capital Prive in this round.

Biophytis CEO and founder Stanislas Veillet said the arrival of Metabrain Research as a shareholder marks a step change in a partnership that the company has pursued for several years in the SARCOB project.

"It will reinforce our capacity to develop drug candidates derived from our portfolio of nutraceutical active substances, with the aim of signing co-development contracts with pharmaceutical companies," Veillet added.

Seventure partners general manager Isabelle de Cremoux said, "Biophytis is a pioneer in this field and this financing will allow it to accelerate its development with a strategy targeting both drugs and nutrition."

Metabrain Research CEO Valerie Autier said the company believe the strategic partnership between its two companies in both the scientific and marketing fields will allow to develop a portfolio of innovative projects.

"We will be able to offer full coverage of metabolic diseases through a joint nutraceutical and pharmaceutical approach," Autier added.